Plenty of platforms will write a GLP-1 prescription in fifteen minutes after a form and a photo. That feels like progress, so it is worth saying plainly why labs come first at GoodLife Health. The reason is not caution for its own sake. The labs change the clinical answer and a prescription written without them is a guess wearing a white coat. Some people who want a GLP-1 need something else first. Some need it at a different dose than they expect. Others have a marker sitting in the blood that changes which medication is the right one.
At GoodLife Health the sequence is fixed. One comprehensive Biomarker Audit comes before any prescription and it repeats every 90 days, four per year, inside the $299 monthly membership. Here is what the first draw actually decides and why skipping it costs more than it saves.
- The first panel establishes baseline HbA1c, fasting insulin, lipids, ApoB, Lp(a) and hs-CRP before any medication is chosen.
- Those numbers change the clinical answer: which medication, what dose, what to watch and how success is measured.
- The quarterly audit that follows turns the prescription into a measured protocol rather than an open-ended subscription.
- The $299 fee covers the doctor and the labs. Medication is billed separately by the pharmacy at pharmacy cost with zero markup.
What the first draw decides
A GLP-1 changes appetite, weight and glucose handling. Those effects land on a system that is already in a particular state and the baseline panel is how that state gets described before anything moves. HbA1c and fasting insulin establish where glucose handling sits today. The lipid panel, ApoB and Lp(a) establish cardiovascular context, because weight-loss medication decisions should never be made blind to lipid risk. hs-CRP adds the inflammation line. Full thyroid and hormone panels rule out the drivers that look like weight problems and are actually thyroid or hormone problems.
Each of those markers has a decision attached. A fasting insulin far above where it should be shifts the conversation toward insulin resistance as the primary problem, with the GLP-1 as one tool in a larger protocol rather than the whole answer. A thyroid result outside what symptoms suggest redirects the whole plan before any prescription is written. An Lp(a) finding changes how aggressively the lipid markers should be managed alongside any weight work. None of these decisions can be made from a photo and a form, which is why the industry's platforms that never check labs are not cutting a corner. They are skipping the diagnosis.
There is also the honesty question about results. A clinician who never drew a baseline cannot tell you what the medication changed. The quarterly audit is what makes progress a measurement rather than a feeling and it is why the membership is built around the panel rather than around the prescription.
What the critique of the fifteen-minute model actually is
The market has split into two shapes. In one, the platform earns its margin on the medication and the clinical step is the cost center, so everything about the flow is engineered to reach the prescription quickly: short forms, generous qualifying answers, no labs, no baseline, no reader. In the other, the clinician earns the fee and the medication is passed through at cost, so the incentive runs the opposite direction: diagnose properly, titrate to the least effective dose and keep measuring.
The second shape is ours. The fee is $299 a month and it never changes with the prescription, because medication is not our revenue. When a branded GLP-1 is clinically indicated, your clinician sends it to the pharmacy you choose and the pharmacy bills you at its own price. There is no molecule upcharge and no dose upcharge. One flat fee for the doctor, zero markup on the medicine. That structure is why the labs can come first rather than last: nobody here needs the prescription to happen for the economics to work.
It is also why we will not prescribe compounded GLP-1s under any circumstance. The fifteen-minute model and the compounded vial are usually the same business. Branded, FDA-approved product only, Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo, with the diagnosis in front of the prescription.
What the sequence looks like in practice
You complete the eligibility check, which is free and a clinician reviews it. If the picture looks like a fit, the $598 hold covering the first two months is placed and the first Biomarker Audit is scheduled at a patient service center near you. The intake visit happens with the results on the table and that is where the medication conversation happens, informed by your own numbers rather than by a quiz. If a branded GLP-1 is indicated, the prescription goes to your pharmacy and the pharmacy bills you at cost. If something else is the actual driver, the protocol targets that instead and you have the labs to show for it either way.
From there the audit repeats every 90 days. Dose conversations happen against the trend in fasting insulin, HbA1c and the rest of the panel, with the goal of the least medicine that gets the most result. If you want the first-charge arithmetic in full, what the $598 start covers walks through it line by line. The hold is released and you are never charged if a clinician cannot accept you into care. Once accepted, the first two months are charged and non-refundable.
The membership is $299 a month with a two-month start: $598 for the first two months, held at sign-up and charged only once a clinician accepts you. The first Biomarker Audit comes before any prescription and repeats quarterly. Medication is billed separately by the pharmacy at pharmacy cost with zero markup, branded and FDA-approved only.
Who this is for and who it is not for
This is for the reader who wants the prescription to follow the diagnosis rather than replace it and who has seen enough of the fifteen-minute model to distrust it. It suits the person who wants to know their baseline before anything changes and to measure the change rather than feel it.
It is not for someone who wants a GLP-1 without labs, because that is the one thing we do not sell and no volume of asking changes it. It is not for anyone outside the United States, because our clinicians are licensed in the fifty states. And it is not insurance. The membership pairs with insurance for catastrophic coverage and replaces the primary-care relationship, not the policy.
FAQ
Why do labs need to come before a GLP-1 prescription?
Because the baseline panel changes the clinical answer. HbA1c, fasting insulin, thyroid, lipids and inflammation markers establish what is actually driving the picture, which medication fits, what dose to start at and how success will be measured. A prescription written without them is a guess.
What bloodwork is done before starting a GLP-1?
The Biomarker Audit covers HbA1c, fasting insulin, fasting glucose, a standard lipid panel, ApoB, Lp(a), hs-CRP, a comprehensive metabolic panel, a CBC and full thyroid and hormone panels including TSH with reflex to free T4. It repeats every 90 days so the medication's effect is measured, not assumed.
How long does it take from sign-up to prescription?
The eligibility check is free and reviewed by a clinician. If the picture fits, the first Biomarker Audit is scheduled and the intake visit happens with results on the table, usually within days of the draw. The sequence exists so the prescription, when it is written, is the right one.
Do I have to do labs again every three months?
The audit repeats every 90 days, four times a year, inside the flat fee. That cadence is what turns the prescription into a measured protocol and anchors dose conversations to data. Additional testing beyond that cadence is ordered for a clinical reason and billed at pass-through cost.
Does the membership fee include the medication?
No and we are direct about it. The $299 fee covers the clinician and the quarterly labs. Any prescription is billed separately by the pharmacy you choose at its own price, at pharmacy cost, with zero markup, no molecule upcharge and no dose upcharge from us.
Do you prescribe compounded GLP-1s?
Never. Our clinicians prescribe branded, FDA-approved medication only: Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo. If branded is not clinically appropriate, we do not substitute a compounded copy to keep a subscription alive.
Is this available outside the United States?
No. Our clinicians are licensed to practice in the fifty states and the membership serves United States residents only.
One last thing
The fifteen-minute prescription is fast the way skipping the map is fast. You are still driving somewhere, you just cannot say where when someone asks. If you want the diagnosis before the prescription and the measurement after it, the eligibility check is free, takes a few minutes and never results in a charge unless a clinician accepts you into care.
Related Guides
- What bloodwork to request at your first weight loss visit
- Biomarker audits vs standard blood tests
- Why we will never prescribe compounded GLP-1s
- Is a GLP-1 worth it at $299 a month
- Cardiometabolic Optimization: the definitive guide
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/